Comparing the current results to its competitors, X4 Pharmaceuticals Inc reported Revenue decrease in the 1 quarter 2026 year on year by -90.6 %, faster than the overall decrease of X4 Pharmaceuticals Inc's competitors by -16.39 %, recorded in the same quarter.
June 27, 2024
X4 Pharmaceuticals Achieves Remarkable Results in Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia, Initiates Pivotal Phase 3 CN TrialX4 Pharmaceuticals, a pioneer in the field of rare diseases, has recently announced positive interim clinical data from its ongoing six-month Phase 2 trial of Mavorixafor in patients with Chronic Neutropenia (CN). Additionally, the company has also initiated a pivotal Phase 3 trial in order to further assess the efficacy and safety of Mavorixafor in CN patients.The Phase 2 trial, which evaluated the use of once-daily oral Mavorixafor in combination with stable-dose G-CSF, has yielded promising results. The interim analysis of data from participants at the six-month ...
X4 Pharmaceuticals, a renowned biopharmaceutical company, recently presented additional data from the Phase 2 trial of their drug, Mavorixafor, at the ASH 2023 conference. The accumulated data continue to bolster the case for advancing Mavorixafor into a pivotal, global Phase 3 trial in specific chronic neutropenic disorders. With the company firmly on track to initiate the next phase in the first half of 2024, X4 Pharmaceuticals is poised to make significant strides in addressing the unmet needs of patients suffering from these conditions.
Chronic neutropenia is a rare blood disorder characterized by an unusually low count of neutrophils, a type of white blood cell essential for the immun...
Argenx is a biopharmaceutical company that utilizes its proprietary antibody discovery platform to develop and commercialize transformative antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Their business model focuses on discovering and developing novel antibodies, partnering with pharmaceutical companies for clinical development, and retaining rights to commercialize the therapies in specific regions.
Theriva Biologics Inc operates as a biotechnology company that focuses on the discovery, development, and commercialization of innovative and targeted therapies for various diseases. Their business model is centered around research and development, aiming to create new biologic drugs and bring them to the market to address unmet medical needs.
Rigel Pharmaceuticals Inc is a biotechnology company that operates on a research and development business model. They focus on discovering, developing, and commercializing innovative small molecule drugs to address unmet medical needs. Their goal is to use their scientific expertise and strategic partnerships to bring new treatments to patients in various therapeutic areas.
Sources:
X4 Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on X4 Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
